CMS Considering Obesity Drug Coverage Under Medicare Rx Benefit
Executive Summary
The Centers for Medicare & Medicaid Services is seeking comment on how obesity treatments can be covered under the Medicare Rx benefit despite language in the law that prohibits coverage of "weight loss" drugs
You may also be interested in...
Sanofi-Aventis Expects Broad Label For Acomplia After FDA Obesity Panel
Sanofi-Aventis is interpreting the results of FDA's recent Endocrinologic & Metabolic Drugs Advisory committee on obesity drug development as a sign that its obesity/smoking cessation agent Acomplia will be approved with a broad label
Sanofi-Aventis Expects Broad Label For Acomplia After FDA Obesity Panel
Sanofi-Aventis is interpreting the results of FDA's recent Endocrinologic & Metabolic Drugs Advisory committee on obesity drug development as a sign that its obesity/smoking cessation agent Acomplia will be approved with a broad label
Acomplia Pricing Likely To Follow Statin Model, Sanofi Says
Sanofi is likely to price the weight loss/smoking cessation agent Acomplia on par with the daily cost of statin therapy, the company suggested during an Aug. 31 analyst call